Pulmozyme - Dornase alfa
Roche
Description
Mucolytic to facilitate expectoration by reducing sputum viscosity.
• Over 5 years: inhalation of nebulised solution (by jet nebuliser), 2,500 units (2.5 mg) once daily (patients over 21 years may benefit from twice daily dosage).
Indications
To improve the pulmonary function of cystic fibrosis patients with a forced vital capacity (FVC) of >40% of predicted.
Sizes Available
Pulmozyme nebuliser solution, 2.5 mg/2.5 ml ampoules, 30 ampoulesÂ
More on: Mucolytics , Dornase alfa